title: A mucous histochemical and immunohistochemical study of precancerous and neoplastic lesions in the human pancreas.
abstract: A total of 44 cases of pancreatic lesions, including hyperplasia (six) cases, adenoma (mucinous cystadenomas [eight] and intraductal papillary adenoma [eight]), noninvasive intraductal papillary tumors (five), and invasive ductal carcinomas (17) were investigated possibly to establish a diagnostic marker. We examined the type of mucin secreted and immunoreactivities of antibodies to ras-p21 and c-erB-2 oncogene products. A significant decrease in the amount of mucin was found in invasive lesions, and this was associated with a shift toward production of neutral mucins and especially sialomucins. Hyperplasia and adenoma, in contrast, demonstrated a predominance of neutral mucin. The sulfated mucins found in normal epithelium were only very weakly stained in any of the tumor types. Thirty-three percent of non-invasive intraductal papillary tumors and 88% of invasive ductal adenocarcinomas demonstrated strong binding of the ras-p21 antibody. In contrast no obvious differences in expression of c-erbB-2 were evident between the groups. In conclusion, a combined mucin histochemical/immunohistochemical approach may facilitate accurate diagnosis.
authors.affiliation: Department of Internal Medicine, Second Hospital, Fujita Health University School of Medicine, Nagoya, Japan.
authors.forename: K
authors.initials: K
authors.lastname: Yamao
authors.forename: S
authors.initials: S
authors.lastname: Nakazawa
authors.forename: M
authors.initials: M
authors.lastname: Fujimoto
authors.forename: H
authors.initials: H
authors.lastname: Tsuda
authors.forename: K
authors.initials: K
authors.lastname: Matsumoto
authors.forename: T
authors.initials: T
authors.lastname: Iwase
mesh_terms: D014408:Biomarkers, Tumor / Q000032:analysis*; D066246:ErbB Receptors / Q000032:analysis; D011905:Genes, ras; D006801:Humans; D007150:Immunohistochemistry; D009077:Mucins / Q000032:analysis*; D010190:Pancreatic Neoplasms / Q000737:chemistry / Q000175:diagnosis* / Q000473:pathology; D016133:Polymerase Chain Reaction; D011230:Precancerous Conditions / Q000737:chemistry / Q000175:diagnosis* / Q000473:pathology; D011518:Proto-Oncogene Proteins / Q000032:analysis; D016283:Proto-Oncogene Proteins p21(ras) / Q000032:analysis; D018719:Erb-b2 Receptor Tyrosine Kinases
chemical_list: D014408:Biomarkers, Tumor; D066246:ErbB Receptors; D009077:Mucins; D011518:Proto-Oncogene Proteins; D016283:Proto-Oncogene Proteins p21(ras); D018719:Erb-b2 Receptor Tyrosine Kinases; C501009:HRAS protein, human